BR112022018251A2 - Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma - Google Patents
Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesmaInfo
- Publication number
- BR112022018251A2 BR112022018251A2 BR112022018251A BR112022018251A BR112022018251A2 BR 112022018251 A2 BR112022018251 A2 BR 112022018251A2 BR 112022018251 A BR112022018251 A BR 112022018251A BR 112022018251 A BR112022018251 A BR 112022018251A BR 112022018251 A2 BR112022018251 A2 BR 112022018251A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapy
- nirogacestat
- combination therapy
- bcma
- bcma targeted
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 229950001637 nirogacestat Drugs 0.000 title abstract 3
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title abstract 2
- 238000002626 targeted therapy Methods 0.000 title abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
- 208000023761 AL amyloidosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000011748 cell maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
TERAPIA DE COMBINAÇÃO COM NIROGACESTAT E TERAPIA DIRIGIDA A BCMA E USOS DA MESMA. A presente invenção refere-se a métodos para tratar câncer ou amiloidose de cadeia leve em um indivíduo em necessidade dos mesmos compreendendo administrar uma terapia de combinação compreendendo uma quantidade eficaz de Forma A de brometo di-hidratgado de nirogacestat e uma terapia dirigida a antígeno de maturação de célula B (BCMA) ao indivíduo e usos dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018251A2 true BR112022018251A2 (pt) | 2022-11-08 |
Family
ID=75396879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018251A BR112022018251A2 (pt) | 2020-03-13 | 2021-03-12 | Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (pt) |
| EP (1) | EP4132515A1 (pt) |
| JP (1) | JP2023517243A (pt) |
| KR (1) | KR20230009873A (pt) |
| CN (1) | CN115916188A (pt) |
| AR (1) | AR121566A1 (pt) |
| AU (1) | AU2021236340A1 (pt) |
| BR (1) | BR112022018251A2 (pt) |
| CA (1) | CA3171267A1 (pt) |
| CL (1) | CL2022002479A1 (pt) |
| CO (1) | CO2022014388A2 (pt) |
| IL (1) | IL296075A (pt) |
| MX (1) | MX2022011258A (pt) |
| PE (1) | PE20230614A1 (pt) |
| TW (1) | TW202200132A (pt) |
| WO (1) | WO2021183934A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023096954A1 (en) * | 2021-11-23 | 2023-06-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of nirogacestat salts |
| US20230372301A1 (en) | 2022-05-20 | 2023-11-23 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| WO2024025968A1 (en) * | 2022-07-28 | 2024-02-01 | Springworks Therapeutics, Inc. | Treatment of multiple myeloma |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| MX2018000999A (es) * | 2015-07-24 | 2018-11-09 | Oncotracker Inc | Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. |
| ES2949364T3 (es) * | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
| EP3615055A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| AU2018359907A1 (en) * | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| JP2021526517A (ja) * | 2018-05-24 | 2021-10-07 | アヤラ ファーマシューティカルズ インコーポレイテッド | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物および免疫療法剤を含む組成物ならびにそれらの使用方法 |
| KR20210016390A (ko) * | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| JP2022529332A (ja) * | 2019-04-10 | 2022-06-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗ＢＣＭＡ抗体及びγ－セクレターゼ阻害剤を使用した併用療法 |
| WO2021029854A1 (en) * | 2019-08-09 | 2021-02-18 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
-
2021
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en unknown
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Search and Examination
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 JP JP2022554833A patent/JP2023517243A/ja active Pending
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
-
2022
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230121547A1 (en) | 2023-04-20 |
| CA3171267A1 (en) | 2021-09-16 |
| TW202200132A (zh) | 2022-01-01 |
| JP2023517243A (ja) | 2023-04-24 |
| WO2021183934A1 (en) | 2021-09-16 |
| AR121566A1 (es) | 2022-06-15 |
| CL2022002479A1 (es) | 2023-08-18 |
| CN115916188A (zh) | 2023-04-04 |
| PE20230614A1 (es) | 2023-04-14 |
| CO2022014388A2 (es) | 2023-02-16 |
| EP4132515A1 (en) | 2023-02-15 |
| KR20230009873A (ko) | 2023-01-17 |
| IL296075A (en) | 2022-11-01 |
| AU2021236340A1 (en) | 2022-09-29 |
| MX2022011258A (es) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018251A2 (pt) | Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| CY1123043T1 (el) | Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων | |
| NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BR112015000660A2 (pt) | uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car. | |
| CY1114644T1 (el) | Χρηση ραδιοεπισημασμενων παραγωγων θειοφλαβινης στην απεικονιση αμυλοειδους για την αξιολογηση αντι-αμυλοειδικων θεραπειων | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| UY32359A (es) | Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento | |
| TR201903411T4 (tr) | Uzun süreli lokal anestezi için neosaksitoksin kombinasyon formülasyonları. | |
| BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
| BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
| PE20151751A1 (es) | Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| BR112022022599A2 (pt) | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| CY1122746T1 (el) | Ιατρικες αγωγες με βαση την αναμορελινη | |
| CY1126041T1 (el) | Σκευασμα φαρμακου για χρηση στον αποτελεσματικο ελεγχο οξεος ή/και χρονιου πονου | |
| CL2021003170A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CL2022001458A1 (es) | Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc) |